Episode: 64 - Peyton Greenside on AI’s Role in Antibody Engineering, Optimization, and More
Update: 2024-08-13
Description
In this episode of The Chain, host Nimish Gera, Ph.D., vice president of biologics at Mythic Therapeutics, speaks with Peyton Greenside, CSO and co-founder of BigHat Biosciences, about the role of AI and machine learning in antibody engineering and targeting complex modalities, including bispecifics and ADCs. Greenside also discusses the work her organization does, what BigHat is doing to ensure the quality of data to train their AI models with, the methods of approaching harder targets such as GPCRs, and certain properties that AI can optimize better.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
